Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin- based chemotherapy and clinical outcome in advanced colorectal cancer patients

Swiss Medical Weekly

Volumn 139, Issue 49-50, 2009, Pages 724-728

  Liang, Jun ^a   Zhang, Haiping ^a   Yin, Beibei ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Alleles; Colorectal neoplasms genetics; Glutathione S transferase P1 genetics; Oxaliplatin drug therapy; Polymorphisms

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; ISOLEUCINE; OXALIPLATIN; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 74849124366     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Board PG, Baker RT, Chelvanayagam G, Jermiin LS. Zeta, a novel class of glutathione transferases in a range of species from plants to humans. Biochem J. 1997;328:929-35.
2. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, et al. Expression of anionic glutathione S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res. 1989;49:1422-8.
3. Peklak-Scott C, Smitherman PK, Townsend AJ, et al. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008;7(10):3247-55.
4. Watson MA, Stewart RK, Smith GB, et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 1998;19:275-80.
5. Arnould S, Hennebelle I, Canal P, et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39:112-9.
6. Sharma RI, Smith TA. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport. J Nucl Med. 2008;49(8):1386-94.
7. Sanoff HK, Sargent DJ, Campbell ME, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35):5721-7.
8. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III Trial. J Clin Oncol. 2003;21:2059-69.
9. Kim DY, Kim JH, Lee SH, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol. 2003;14:383-7.
10. Suh SH, Kwon HC, Jo JH, et al. Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (Modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer. Cancer Res Treat. 2005;37:279-83.
11. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer. 2005;92:1644-9.
12. Kweekel DM, Koopman M, Antonini NF, et al. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer. 2008;99(8):1316-21.
13. Bennaceur-Griscelli A, Bosq J, Koscielny S, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res. 2004;10(9):3029-34.
14. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphisms and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2002;94:936-42.
15. Nedelcheva Kristensen V, Andersen TI, Erikstein B, et al. Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. Pharmacogenetics. 1998;8:441-7.
16. Peklak-Scott C, Smitherman PK, Townsend AJ, et al. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008;7(10):3247-55.
17. Yasumatsu R, Nakashima T, Uryu H, et al. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy. 2009;55(1):36-41.
18. Harries LW, Stubbins MJ, Forman G, et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997;18:641-4.
19. Ryberg D, Skaug V, Hewer A, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 1997;18:1285-9.
20. Le Morvan V, Smith D, Laurand A, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics. 2007;8(12):1693-703.
21. Kweekel DM, Gelderblom H, Antonini NF, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer. 2009;45(4):572-8.
22. Chakrapani H, Kalathur RC, Maciag AE, et al. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorg Med Chem. 2008;16(22):9764-71.